What are the Tokyo guidelines for the diagnosis and management of choledocholithiasis (common bile duct stones)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tokyo Guidelines for Choledocholithiasis

Note: The question asks about "Tokyo Guidelines," but the provided evidence primarily contains British Society of Gastroenterology (BSG) guidelines from 2017, which represent the most comprehensive and highest-quality guideline evidence available here. The Tokyo Guidelines specifically address acute cholangitis rather than choledocholithiasis management broadly 1, 2. I will provide guidance based on the strongest available evidence for choledocholithiasis management.

Core Management Principle

All patients diagnosed with common bile duct stones (CBDS) should be offered stone extraction if possible, with the greatest benefit seen in symptomatic patients 3.

Diagnostic Approach

Initial Workup

  • Start with transabdominal ultrasound (USS) and liver function tests (LFTs) for all suspected CBDS cases 3
  • Normal results do NOT exclude CBDS if clinical suspicion remains high—proceed with further investigation 3

Risk Stratification Algorithm

Low Likelihood (normal USS and LFTs):

  • Consider alternative diagnosis
  • If suspicion persists, proceed to advanced imaging

Intermediate Likelihood (CBD dilatation with normal LFTs OR abnormal LFTs with normal calibre duct):

  • Proceed to MRCP or EUS 3
  • Both modalities perform similarly: EUS sensitivity 0.95 vs MRCP 0.93; EUS specificity 0.97 vs MRCP 0.96 3

High Likelihood (CBD stone seen on USS, cholangitis features, or triad of pain/duct dilatation/jaundice with gallstone history):

  • Proceed directly to ERCP or surgical extraction 3
  • Further imaging not routinely required unless malignancy is in differential (then obtain CT) 3

Choosing Between MRCP and EUS

MRCP is preferred in most cases because it is:

  • Non-invasive
  • Widely available
  • Can image intrahepatic ducts
  • More cost-effective
  • Suitable for altered anatomy 3

EUS is preferred when:

  • Patient has intracranial metallic clips, pacemakers, mechanical heart valves
  • Claustrophobia or morbid obesity present
  • Appropriately skilled clinician available 3

Treatment Options

Endoscopic Management (ERCP)

Key recommendations:

  • Hospitals managing CBDS must have prompt access to anesthesia-supported ERCP (propofol sedation or general anesthesia) for selected patients, as this improves tolerability and therapeutic success 3
  • Obtain full blood count and INR/PT before biliary sphincterotomy 3
  • For patients at high risk of post-ERCP pancreatitis from repeated pancreatic duct cannulation, insert pancreatic stent in addition to rectal NSAID 3

Surgical Management

For patients undergoing laparoscopic cholecystectomy, laparoscopic bile duct exploration (LBDE)—either transcystic or transductal—is equally valid to perioperative ERCP 3:

  • No difference in efficacy, mortality, or morbidity between approaches
  • LBDE associated with shorter hospital stay (high-quality evidence) 3
  • Both approaches should be considered equally valid treatment options 3

Failed Endoscopic or Surgical Extraction

  • Consider percutaneous radiological techniques if CBDS cannot be extracted with surgery or ERCP 3

Special Considerations for Cholangitis

When cholangitis complicates choledocholithiasis, be aware that:

  • Tokyo Guidelines cholestasis criterion is present in 96% of cases, while inflammation (currently considered "essential") is only present in 76% 4
  • In patients ≥80 years old: Charcot triad is less common, malaise may be the primary symptom, 9% have no pain/fever/jaundice, and altered mental status occurs in 34% 4
  • Carefully distinguish cholangitis from concomitant acute cholecystitis or pancreatitis with choledocholithiasis—false positives occur in these scenarios 1

Critical Pitfalls to Avoid

  1. Do not rely on normal USS/LFTs alone to exclude CBDS in high clinical suspicion cases 3
  2. Do not use ERCP as a diagnostic tool—it carries >5% serious adverse event risk and should be reserved for therapeutic intervention 3
  3. Do not assume elderly patients will present with classic Charcot triad—they often present atypically with malaise or altered sensorium 4
  4. Do not perform MRCP in intermediate-risk patients when EUS or intraoperative cholangiogram is available—these have superior diagnostic characteristics 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.